Skip to main content
SpringerLink
Log in

Multiple sclerosis

Is there a safe time to discontinue therapy in MS?

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

As yet, no clear strategy has been developed for discontinuation of disease-modifying therapy in multiple sclerosis. A recent observational study adds new information, but the most informative patient groups are still to be assessed comprehensively, and several questions need to be addressed in prospective studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Freedman, M. S. et al. Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult. Scler. Relat. Disord. 3, 147–155 (2014).

    Article  Google Scholar 

  2. Bsteh, G. et al. Discontinuation of disease-modifying therapies in multiple sclerosis — clinical outcome and prognostic factors. Mult. Scler. http://dx.doi.org/10.1177/1352458516675751 (2016).

  3. Tobin, W. O. & Weinshenker, B. G. Stopping immunomodulatory medications in MS: frequency, reasons and consequences. Mult. Scler. Relat. Disord. 4, 437–443 (2015).

    Article  CAS  Google Scholar 

  4. Kister, I. et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J. Neurol. Neurosurg. Psychiatry 87, 1133–1137 (2016).

    Article  Google Scholar 

  5. Vellinga, M. M., Castelijns, J. A., Barkhof, F., Uitdehaag, B. M. & Polman, C. H. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70, 1150–1151 (2008).

    Article  CAS  Google Scholar 

  6. Hatcher, S. E., Waubant, E., Nourbakhsh, B., Cravtree-Hartman, E. & Graves, J. S. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 73, 790–794 (2016).

    Article  Google Scholar 

  7. Kappos, L. & European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491–1497 (1998).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mark S. Freedman is at the Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada.,

    Mark S. Freedman

Authors
  1. Mark S. Freedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark S. Freedman.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Freedman, M. Is there a safe time to discontinue therapy in MS?. Nat Rev Neurol 13, 10–11 (2017). https://doi.org/10.1038/nrneurol.2016.192

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.192

  • Springer Nature Limited

Search

Navigation